The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 44.50
Ask: 45.50
Change: -1.50 (-3.23%)
Spread: 1.00 (2.247%)
Open: 46.50
High: 46.50
Low: 44.75
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Aug 2020 09:30

RNS Number : 7832V
Avacta Group PLC
11 August 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Avacta Group plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

PREMIER MITON GROUP PLC

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/08/2020

6. Date on which issuer notified (DD/MM/YYYY):

07/08/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

4.66%

N/A

4.66%

249,155,721

Position of previous notification (if

applicable)

8.13%

N/A

8.13%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BYYW9G87

11,609,794

4.66%

SUBTOTAL 8. A

11,609,794

4.66%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Premier Miton Group Plc

Premier Asset Management Midco Ltd

Premier Asset Management Holdings Ltd

Premier Asset Management Limited

Premier Investment Group Ltd

Premier Fund Managers Ltd

4.66%

4.66%

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional informationxvi

Please note that with effect from 27th April 2020 all investment management related activities for the Premier Miton Group plc will be carried out by Premier Fund Managers Limited. Miton Asset Management Limited and Miton Trust Managers Limited have ceased to carry out regulated activities.

 

Place of completion

LONDON, UK

Date of completion

07/08/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMZGMRRMRGGZG
Date   Source Headline
5th Jan 202111:05 amRNSSecond Price Monitoring Extn
5th Jan 202111:00 amRNSPrice Monitoring Extension
23rd Dec 20207:00 amRNSSubmission of CTA for AVA6000 Pro-doxorubixin
21st Dec 20207:00 amRNSLicense Agreement with Astrea Bioseparations
23rd Nov 20209:05 amRNSSecond Price Monitoring Extn
23rd Nov 20209:00 amRNSPrice Monitoring Extension
23rd Nov 20207:00 amRNSSARS-CoV-2 Rapid Antigen Test Update
18th Nov 20204:40 pmRNSSecond Price Monitoring Extn
18th Nov 20204:36 pmRNSPrice Monitoring Extension
13th Nov 20202:15 pmRNSIssue of Equity
10th Nov 202011:06 amRNSSecond Price Monitoring Extn
10th Nov 202011:00 amRNSPrice Monitoring Extension
9th Nov 20202:06 pmRNSSecond Price Monitoring Extn
9th Nov 20202:01 pmRNSPrice Monitoring Extension
22nd Oct 20201:50 pmRNSDirector/PDMR Shareholding
8th Oct 20209:00 amRNSIssue of Equity
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
30th Sep 202010:35 amRNSLaunch of SARS-CoV-2 BAMS Research Test
29th Sep 20207:00 amRNSAppointment of Joint Broker
28th Sep 20209:00 amRNSPrice Monitoring Extension
28th Sep 20207:00 amRNSInterim Results for the Period Ended 30 June 2020
24th Sep 20207:00 amRNSUpdate on Integumen Collaboration
14th Sep 20207:00 amRNSNotice of Results and Investor Presentation
7th Sep 20207:00 amRNSAvacta to Launch SARS-CoV-2 ELISA Laboratory Test
2nd Sep 20207:00 amRNSExpansion of COVID-19 Test Manufacturing Capacity
20th Aug 20204:45 pmRNSIssue of Equity
19th Aug 20204:41 pmRNSSecond Price Monitoring Extn
19th Aug 20204:36 pmRNSPrice Monitoring Extension
19th Aug 20202:05 pmRNSSecond Price Monitoring Extn
19th Aug 20202:00 pmRNSPrice Monitoring Extension
18th Aug 20203:30 pmRNSIssue of Equity
18th Aug 20207:00 amRNSExpanded Partnership with LG Chem Life Sciences
17th Aug 20207:00 amRNSClarification Regarding Medusa 19 Antibody Test
11th Aug 20209:30 amRNSHolding(s) in Company
11th Aug 20207:00 amRNSTherapeutics Chief Development Officer Appointment
7th Aug 20207:00 amRNSSARS-CoV-2 Antigen Test Clinical Collaboration
6th Aug 20207:00 amRNSCOVID-19 Rapid Antigen Test Manufacturing Partner
29th Jul 20207:00 amRNSExpanded Partnership with Daewoong Pharmaceutical
22nd Jul 20207:00 amRNSUpdate on Adeptrix COVID-19 Diagnostic Test
17th Jul 20204:41 pmRNSSecond Price Monitoring Extn
17th Jul 20204:35 pmRNSPrice Monitoring Extension
13th Jul 20207:00 amRNSCollaboration with Integumen plc
7th Jul 20202:06 pmRNSIssue of Equity
3rd Jul 20204:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20204:35 pmRNSPrice Monitoring Extension
24th Jun 202011:15 amRNSResult of General Meeting
24th Jun 20207:00 amRNSUpdate on COVID-19 Test Development Partnership
22nd Jun 20202:52 pmRNSResult of AGM
18th Jun 20207:00 amRNSUpdate on Affimer® Therapy for COVID-19 Infection

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.